CRMD - CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference | Benzinga
BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15.
The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents. Taurolidine exhibited in vitro antimicrobial activity against all C. auris strains and isolates regardless of geographic source, year of isolation, or clade. There was no evidence that taurolidine activity was affected by resistance to amphotericin B or fluconazole. Based on the in vitro data, catheter lock solutions containing the broad-spectrum antimicrobial taurolidine have the potential to prevent catheter related bloodstream infections (CRBSI) caused by C. auris, including clinical isolates that are resistant to common antifungals.
The abstract is available through the IDWeek conference website.
IDWeek 2023 Conference Abstract:
In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources
Poster #2117
Antony Pfaffle1, Leonard Duncan2, Mariana Castanheira2, Bruce Reidenberg3, Cecilia Carvalhaes2, Jessica Vaughn1 and Phoebe Mounts1
1CorMedix Inc.; 2JMI Laboratories; 3Weill Cornell Medicine
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic ...